Company news
Gensight Biologics Sa (EURONEXT:SIGHT) news
Every Gensight Biologics Sa press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
GenSight Biologics S A : Reports Interim Financial Results for the First Half of 2026 and Provides Business Updates
September 29, 2026
GenSight Biologics Provides September 2026 Business Updates
September 8, 2026
GenSight Biologics Reports Cash Position as of June 30, 2026, and Provides Business Updates
July 8, 2026
GenSight Biologics Announces the Results of its Combined General Meeting of May 19, 2026
May 20, 2026
GenSight Biologics to Hold its Combined General Meeting on May 19, 2026
May 18, 2026
GenSight Biologics Announces Publication on Matching-Adjusted Indirect Comparison of Leber Hereditary Optic Neuropathy Treatments
May 11, 2026
GenSight Biologics Announces Annual General Meeting to Take Place on May 19, 2026
April 28, 2026
GenSight Biologics Announces the Filing of its 2025 Universal Registration Document
April 15, 2026
GenSight Biologics Reports Cash Position and Revenue from Early Access Program as of March 31, 2026
April 7, 2026
GenSight Biologics Confirms Definitive Full-Year 2025 Consolidated Financial Results Are in Line with Estimates
April 3, 2026
GenSight Biologics Reports Estimated Full-Year Consolidated Financial Results for 2025
March 27, 2026
The 15-20 National Hospital and GenSight Biologics Announce the First Treatments in the French Named Patient Early Access Program (AAC) for GS010/LUMEVOQ®
March 20, 2026
GenSight Biologics Announces the Closing of its Nearly €1.7 Million Fundraising
March 18, 2026
GenSight Biologics Announces Successful Fundraising Worth Nearly €1.7 Million
March 10, 2026
GenSight Biologics Provides Updates about GS010/LUMEVOQ® Early Access Programs and the Ongoing REVISE Study
March 9, 2026
GenSight Biologics Bolsters Regulatory Leadership in US and Europe with Two Senior Appointments
February 18, 2026
The 15-20 National Hospital and GenSight Biologics Announce the Treatment of the First Patient in the GS010/LUMEVOQ® REVISE Study
February 10, 2026
GenSight Biologics Announces the Results of its Extraordinary General Meeting of January 28, 2026
January 28, 2026
GenSight Biologics Reports Cash Position as of December 31, 2025, and Provides Business Updates
January 8, 2026
GenSight Biologics Announces Closing of Fundraising Worth Nearly EUR 2.9 Million
January 7, 2026
GenSight Biologics Announces Successful Fundraising Amounting to Nearly €2.9 Million
December 29, 2025
GenSight Biologics Announces Regulatory Authorization for Early Access Treatment with GS010/LUMEVOQ® in Israel
December 22, 2025
GenSight Biologics Announces the Granting of Compassionate Use Authorization (CUA/AAC) for GS010/LUMEVOQ® in France
December 22, 2025
GenSight Biologics Announces Regulatory Approval for GS010/LUMEVOQ® REVISE Dose-Ranging Study in France
December 2, 2025
Inherited Retinal Disease Market Analysis Report 2025-2035, Featuring Profiles of Novartis, GenSight Biologics, Aldeyra Therapeutics, and Spark Therapeutics
November 19, 2025
GenSight Biologics Announces Closing of Fundraising Worth Nearly EUR 2 Million
November 13, 2025
GenSight Biologics Announces Successful Fundraising Amounting to Nearly €2 Million
November 10, 2025
GenSight Biologics Announces Regulatory Authorizations for Individual Patient Expanded Access Treatment with GS010/LUMEVOQ® in the US
October 30, 2025
GenSight Biologics Reports Cash Position as of September 30, 2025
October 7, 2025
GenSight Biologics Announces Closing of Fundraising Worth Nearly EUR 3.7 Million
October 1, 2025
GenSight Biologics Reports Interim Financial Results for the First Half of 2025
September 29, 2025
GenSight Biologics Announces Successful Fundraising Amounting to Nearly EUR 3.7 Million
September 26, 2025
GenSight Biologics Postpones Release of 2025 Half-Year Financial Results
August 28, 2025
OSE Immunotherapeutics Appoints Thomas Gidoin as Chief Financial Officer
August 20, 2025
GenSight Biologics Announces Publication on Predictors of Final Visual Outcome in Patients Treated with LUMEVOQ® Gene Therapy
July 17, 2025
GenSight Biologics Reports Cash Position as of June 30, 2025
July 8, 2025
GenSight Biologics Announces the Closing of the Company’s c. €4 Million Private Placement
July 3, 2025
GenSight Biologics Announces Successful Completion of a Private Placement of Close to EUR 4 Million
July 1, 2025
GenSight Biologics Announces Significant Milestone in New Manufacturing Partnership with Catalent
June 26, 2025
GenSight Biologics Reaches Agreement with ANSM for Opening of LUMEVOQ® Named Early Access Program (AAC) in France
June 12, 2025
GenSight Biologics Announces Approval of All Resolutions Supported by the Board of Directors at the Combined General Meeting of May 13, 2025
May 13, 2025